PhotoCure ASA - Annual General Meeting

The Annual General Meeting in PhotoCure ASA took place on 20 March 2002. The General Meeting approved the Director's Report and the Annual Accounts, as well as the Board of Directors' proposed settlement of the deficit of 2001.

The new Board of Directors of PhotoCure ASA consists of:

Erik Engebretsen, chairman
Per-Olof Mårtensson, deputy chairman
Halvor Bjerke
Tharald Brøvig
Lars Lindegren
Åse Aulie Michelet

In accordance with the proposals of the Board of Directors, the General Meeting also resolved to grant authority to the Board to increase the share capital and to acquire own shares. 
   
 PhotoCure ASA is a Norwegian listed company established in 1993. Its mission is to develop and sell pharmaceuticals and medical devices based on proprietary photodynamic technologies. The company develops products for skin cancer and other skin diseases, internal cancer, gene therapy and cancer vaccines. Metvix® PDT is approved for the treatment of basal cell carcinoma (skin cancer) and actinic keratosis (pre-cancerous skin lesions). PhotoCure's second pharmaceutical product, Hexvix®, is currently undergoing phase III clinical trials for bladder cancer detection.

PCI Biotech AS was established as a subsidiary of PhotoCure ASA to develop and commercialise new transfection technologies for the research market as well as products in oncology and gene therapy.

For more information contact:

PhotoCure ASA
Attn. Vidar Hansson, CEO
Hoffsveien 48
0377 Oslo
Norway

www.photocure.com

E-mail: vh@photocure.no
Telephone: +47 22 06 22 10
Fax: +47 22 06 22 18
Mobile: +47 90 73 78 72